A treatment choice for breast cancer has recently been determined based on the current standard clinicopathological biomarkers, including the expression levels of hormone receptors (HRs; ER and progesterone receptor [PgR]), human epidermal growth factor receptor 2 (HER2), and Ki67 [7]. This evidence concerns the gene PGR and breast carcinoma.